Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
2002
We initiated a randomized, double-blinded, placebo-controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6-week open-label study of IVIG, positive trends were observed. © 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 549–552, 2002
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
68
Citations
NaN
KQI